| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000014694 |
| Receipt No. | R000017021 |
| Official scientific title of the study | Clinical studies on the safety and efficacy of platelet rich plasma used in anterior cruciate ligament reconstruction |
| Date of disclosure of the study information | 2014/08/01 |
| Last modified on | 2017/07/31 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Clinical studies on the safety and efficacy of platelet rich plasma used in anterior cruciate ligament reconstruction | |
| Title of the study (Brief title) | Clinical studies on the safety and efficacy of platelet rich plasma used in anterior cruciate ligament reconstruction | |
| Region |
|
|
| Condition | ||
| Condition | rupture of anterior cruciate ligament | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To clarify the safety of PRP use in ACL reconstruction |
| Basic objectives2 | Safety |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | Phase I |
| Assessment | |
| Primary outcomes | The presence or absence of adverse events in the follow-up period and at the time of surgery
1.Change in the vital signs when it is inserted into the intra-articular ligament with PRP 2.Joint fluid culture of postoperative drain effluent 3.Swelling of knee joint during follow-up times 4.Infection sign during 2weeks |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |||
| No. of arms | 1 | ||
| Purpose of intervention | Treatment | ||
| Type of intervention |
|
||
| Interventions/Control_1 | Use of PRP to the ACL reconstruction patients | ||
| Interventions/Control_2 | |||
| Interventions/Control_3 | |||
| Interventions/Control_4 | |||
| Interventions/Control_5 | |||
| Interventions/Control_6 | |||
| Interventions/Control_7 | |||
| Interventions/Control_8 | |||
| Interventions/Control_9 | |||
| Interventions/Control_10 | |||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients operated ACL reconstruction in our hospital | |||
| Key exclusion criteria | History of infection(septic arthritis of the knee, femur / tibia osteomyelitis) /
compromised host (Child-Pugh score A-C, diabetes, immunodeficiency, chronic renal failure, cirrhosis of the liver) - autoimmune disease(Various collagen diseases such as rheumatoid arthritis, systemic lupus erythematosus) Anemia (hemoglobin 10 g / dl or less) Blood disease(Coagulation and fibrinolysis abnormalities such as hemophilia) Anticoagulant used (such as aspirin, warfarin) Patients with a suspected history of malignancy within 5 years prior to the date of consent Patients who study physician determines that it is not suitable as a target |
|||
| Target sample size | 5 | |||
| Research contact person | |
| Name of lead principal investigator | Akihiro Kanamori |
| Organization | Medicine Medical |
| Division name | Orthopaedic Surgery |
| Address | 1-1-1 Tennodai,Ibaraki,JAPAN |
| TEL | 029-853-3219 |
| kanamori@md.tsukuba.ac.jp | |
| Public contact | |
| Name of contact person | YU TANIGUCHI |
| Organization | Univercity of Tsukuba |
| Division name | Orthopaedic surgery |
| Address | 1-1-1 Tennodai,Ibaraki,JAPAN |
| TEL | 029-853-3219 |
| Homepage URL | |
| cindy.forever911@tsukuba-seikei.jp | |
| Sponsor | |
| Institute | University of tsukuba
Department of Orthopaedic Surgery |
| Institute | |
| Department | |
| Funding Source | |
| Organization | none |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete | |||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000017021 |